Skip to main
IRD
IRD logo

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc. is advancing its clinical-stage pipeline with a focus on therapies for inherited retinal diseases, showcasing significant efficacy improvements among patients across various treatments. Key results indicate a commendable increase in patient-reported satisfaction and visual capabilities, with 20.6% of treated patients achieving meaningful visual gains compared to only 6.1% in the placebo group, underscoring strong therapeutic potential. Furthermore, regulatory guidance implying an accelerated pathway adds a positive dimension to the company's prospects, enhancing investor confidence in its long-term growth and market positioning.

Bears say

Opus Genetics Inc has reported a decrease in R&D expenses for the quarter, totaling $6.4 million, down from $9.0 million in the same period the previous year, indicating potential cost-cutting measures amidst ongoing financial pressure. The company has consistently incurred significant losses since its inception, raising concerns about its long-term viability and ability to sustain operations. Furthermore, the increasing competition from emerging therapies targeting similar retinal diseases poses a significant risk to Opus’s market penetration and pricing, potentially jeopardizing its future revenue prospects.

Opus Genetics (IRD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.